Haruaki Tomioka

Type II Alveolar Cells Play Roles in Macrophage‐Mediated Host Innate Resistance to Pulmonary Mycobacterial Infections by Producing Proinflammatory Cytokines

Katsumasa Sato, Haruaki Tomioka, Toshiaki Shimizu et al. · The Journal of Infectious Diseases · 2002 · 93 citations · Full text

Life Sciences, Immunology, Microbiology +14

[Development of antituberculous drugs: current status and future prospects].

Haruaki Tomioka, Kenji Namba · PubMed · 2006 · 74 citations

Public Health, Infectious Diseases, Pharmacotherapy +16

Unique Macrophages Different from M1/M2 Macrophages Inhibit T Cell Mitogenesis while Upregulating Th17 Polarization

Yutaka Tatano, Toshiaki Shimizu, Haruaki Tomioka · Scientific Reports · 2014 · 59 citations · Full text

Life Sciences, Immunology, Microbiology +17

Comparative In Vitro Antimicrobial Activities of the Newly Synthesized Quinolone HSR-903, Sitafloxacin (DU-6859a), Gatifloxacin (AM-1155), and Levofloxacin against <i>Mycobacterium tuberculosis</i> and <i>Mycobacterium avium</i> Complex

Haruaki Tomioka, Katsumasa Sato, Tatsuya Akaki et al. · Antimicrobial Agents and Chemotherapy · 1999 · 58 citations · Full text

Medicine, Infectious Diseases, Microbiology +12

Comparative Antimicrobial Activities of the Newly Synthesized Quinolone WQ-3034, Levofloxacin, Sparfloxacin, and Ciprofloxacin against <i>Mycobacterium tuberculosis</i> and <i>Mycobacterium avium</i> Complex

Haruaki Tomioka, Katsumasa Sato, Hiroko Kajitani et al. · Antimicrobial Agents and Chemotherapy · 2000 · 56 citations · Full text

Medicine, Infectious Diseases, Pharmacology +13